期刊文献+

粉尘螨变应原ProDer f 1编码基因重组pET28a-YARA-Ihc体系的构建及表达

Construction and expression of the recombinant plasmid pET28a-YARA-Ihc-ProDer f 1 of Dermatophagoides farina
下载PDF
导出
摘要 目的构建粉尘螨变应原ProDerf1原核表达载体pET28a-YARA—IhC—ProDerf1,为评价其免疫治疗效果奠定基础。方法用分子克隆技术构建出表达载体pET28a—YARA—IhC—ProDerf1,在E.coli BL21(DE3)中表达融合蛋白YARA-IhC-ProDer f 1,并进行Ni^(2+)-NTA树脂柱亲和层析以纯化蛋白。结果经测序证实成功构建了表达载体pET28a-YARA-IhC-ProDer f 1,YARA-IhC-ProDer f 1融合蛋白在E.coli BL21(DE3)中得到表达,纯化后的蛋白浓度为278μg/ml。SDS-PAGE和Westem blot分析表明纯化蛋白为目的蛋白YARA-IhC-ProDer f 1。结论已成功制备出pET28a—YARA—IhC-ProD—er f 1原核表达载体,融合蛋白得到表达和纯化。 Objective To construct the prokaryotic expression vector pET28a-YARA-Ihc-ProDer f 1 and provide the foundation for exploring the fusion protein effect as vaccine for specific immunotherapy. Methods Two oligonucleotides encoding YARA were synthesized and annealed to generate YARA-encoding DNA. The fused genes, YARA-Ihc-ProDer f 1 was constructed and inserted into the prokaryotic expression vector pET28a(+). The fusion protein YARA-Ihc-ProDer f 1 induced with IPTG in E.coli BL21(DE3) was purified with Ni2+-resin affinity chromatography and confirmed with SDS-PAGE and Western blot. Results Sequence analysis confirmed the construction of the expression vector pEt28a-YARA-Ihc-ProDer f 1 successfully, the fusion protein YARA-Ihc-ProDer f 1 was expressed and purified with the concentration of 278μg/ml. SDS-PAGE and Western blot demonstrated the fusion protein was YARA-Ihc-ProDer f 1. Conclusion The recombinant prokaryotic expression vectors, pET28a(+)-YARA-Ihc-ProDer f 1 was successfully constructed, and the fusion protein was expressed and purified .
出处 《热带病与寄生虫学》 2014年第3期125-128,共4页 Journal of Tropical Diseases and Parasitology
基金 国家自然科学基金资助项目(81172790)
关键词 细胞穿透肽 粉尘螨 恒定链 变应原 Cell penetrating peptides, Dermatophagoidesfarina, invariant chain, allergens
  • 相关文献

参考文献20

  • 1Pawankar R, Baena-Cagnani CE, Bousquet J, et al. State of world allergy report 2008: allergy and chronic respiratory diseases. World Allergy Organ J, 2008, 1 (6 Suppl): S4-S17.
  • 2Calderon MA, Demoly P, Gerth van Wijk R, et al. EAAC1: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Aller- gy, 2012, 2 (1): 20.
  • 3Takai T, Kato T, Hatanaka H,et al. Modulation of aUerge- nicity of major house dust mite allergens Der f 1 and Der p 1 by interaction with an endogenous ligand. J Immunol, 2009, 183 (12): 7958-7965.
  • 4Zock JP, Heinrich J, Jarvis D, et al. Distribution and deter- minants of house dust mite allergens in Europe: the Europe- an Community Respiratory Health Survey II. J Allergy Clin Immunol, 2006, 118 (3): 682-690.
  • 5Thomas WR, Hales BJ and Smith WA. House dust mite al- lergens in asthma and allergy. Trends Mol Med, 2010, 16 (7): 321-328.
  • 6Pipet A, Botturi K, Pinot D, et al. Allergen-specific immu- notherapy in allergic rhinitis and asthma. Mechanisms and proof of eiticacy. Respir Med, 2009, 103 (6): 800-812.
  • 7Blaser K. Allergen dose dependent cytokine production reg- ulates specific IgE and IgG antibody production. Adv Exp Med Biol, 1996, 409 (1): 295-303.
  • 8Valenta R, Linhart B, Swoboda I, et al. Recombinant aller- gens for allergen-specific immunotherapy: 10 years anniver- sary of immunotherapy with recombinant allergens. Allergy, 2011, 66 (6); 775-783.
  • 9李辉严,马三梅,邹泽红,王永飞,陶爱林.重组低过敏原性粉尘螨过敏原的表达及鉴定[J].细胞与分子免疫学杂志,2010,26(5):447-449. 被引量:2
  • 10Sanderson S, Frauwirth K and Shastri N. Expression of en- dogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc Natl Acad Sci U S A, 1995, 92 (16): 7217-7221.

二级参考文献10

  • 1王顺涛,冯健男,黎燕,沈倍奋.抗IgE抗体的研究进展[J].细胞与分子免疫学杂志,2004,20(5):640-642. 被引量:6
  • 2Thomas WR, Smith WA, Hales B J, et al. Characterization and immunobiology of house dust mite allergens[ J]. Int Arch Allergy lmmunol, 2002, 129(1):1 -18.
  • 3Niederberger V, Valenta R. Molecular approaches for new vaccines against allergy[ J]. Expert Rev Vaccines, 2006, 5( 1 ) : 103 -110.
  • 4Purohit A, Niederberger V, Kronqvist M, et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives[J]. Clin Exp Allergy, 2008, 38(9) : 1514 - 1525.
  • 5Chapman MD, Platts-Mills TA. Purification and characterization of the major allergen from Dermatophagoides pteronyssinus-antigen PI [ J]. J Immunol, 1980, 125(2) : 587 -592.
  • 6Walgraffe D, Matteotti C, El Bakkoury M, et al.A hypoallergenic variant of Der p 1 as a candidate for mite allergy vaccines[J]. J Allergy Clin Immunol, 2009, 123(5): 1150-1156.
  • 7Chruszcz M, Chapman MD, Vailes LD, et al. Crystal structures of mite allergens Der f 1 and Der p 1 reveal differences in surface-exposed residues that may influence antibody binding[ J]. J Mol Biol, 2009, 386(2) : 520 -530.
  • 8Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 [ J ]. Nature, 1970, 227 ( 5259 ) : 680 - 685.
  • 9Takai T, Kato T, Yasueda H, et al. Analysis of the structure and allergenicity of recombinant pro-and mature. Der p 1 and Der f 1 : major conformational lgE epitopes blocked by prodomains[ J]. J Allergy Clin Immunol, 2005, 115(3) : 555 -563.
  • 10Wan H, Winton HL, Soeller C, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions [ J ]. J Clin Invest, 1999, 104(1): 123-133.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部